Schoenfeld, J. D., Giobbie-Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C., Hubbard, J., Arnold, S. M., Abbruzzese, J. L., Jabbour, S. K., Uboha, N. V., Stephans, K. L., Johnson, J. M., Park, H., Villaruz, L. C., Sharon, E., Streicher, H., Ahmed, M. M., Lyon, H., Cibuskis, C., Lennon, N., Jhaveri, A., Yang, L., Altreuter, J., Gunasti, L., Weirather, J. L., Mak, R. H., Awad, M. M., Rodig, S. J., Chen, H. X., Wu, C. J., Monjazeb, A. M., & Hodi, F. S. (2022). durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet oncology, 23(2), 279–291. http://access.bl.uk/ark:/81055/vdc_100150526824.0x000015